Published in Pharma Investments, Ventures and Law Weekly, November 5th, 2006
The multi-year grant is funded through the National Institutes of Health (NIH) by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
"Affinergy is very excited to move forward with this important program," said Jonathan Gindes, Affinergy's CFO & SVP of Business Development. "This further validates our technology as reviewed by scientific peers and acknowledges the progress that was demonstrated by our staff during phase I of the program....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.